Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to -$2.5 million.

  • Cytosorbents' Net Cash Flow rose 1184.9% to -$2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.1 million, marking a year-over-year decrease of 24294.3%. This contributed to the annual value of -$5.8 million for FY2024, which is 2895.87% up from last year.
  • Per Cytosorbents' latest filing, its Net Cash Flow stood at -$2.5 million for Q3 2025, which was up 1184.9% from -$1.6 million recorded in Q2 2025.
  • In the past 5 years, Cytosorbents' Net Cash Flow ranged from a high of $5.7 million in Q4 2023 and a low of -$12.7 million during Q2 2022
  • Over the past 5 years, Cytosorbents' median Net Cash Flow value was -$2.9 million (recorded in 2021), while the average stood at -$3.3 million.
  • In the last 5 years, Cytosorbents' Net Cash Flow crashed by 34014.85% in 2022 and then soared by 113716.89% in 2023.
  • Cytosorbents' Net Cash Flow (Quarter) stood at -$7.2 million in 2021, then soared by 92.46% to -$546406.0 in 2022, then surged by 1137.17% to $5.7 million in 2023, then crashed by 140.56% to -$2.3 million in 2024, then dropped by 9.72% to -$2.5 million in 2025.
  • Its Net Cash Flow was -$2.5 million in Q3 2025, compared to -$1.6 million in Q2 2025 and $3.3 million in Q1 2025.